Ontario's FAST Program Delivers New Hope with Itovebi Cancer Drug

MISSISSAUGA, ON – February 24, 2026 – Patients in Ontario with a specific and aggressive form of advanced breast cancer are gaining access to a promising new treatment up to a year earlier than expected, thanks to a landmark provincial initiative. Hoffmann-La Roche Limited (Roche Canada) has announced that its new therapy, Itovebi® (inavolisib), is the first breast cancer drug to be publicly funded through Ontario's innovative Funding Accelerated for Specific Treatments (FAST) program.

This development marks a significant shift in the often-criticized landscape of Canadian drug access, where patients have historically faced some of the longest wait times for new medicines among developed nations. For those diagnosed with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative breast cancer, the accelerated access to Itovebi represents a crucial new timeline of hope.

A New Model to Combat the Waiting Game

Launched in October 2025, the FAST program is a three-year pilot project designed to dismantle the bureaucratic delays that have long plagued Canada's drug reimbursement system. Traditionally, after a drug is approved as safe and effective by Health Canada, a lengthy price negotiation process begins through the pan-Canadian Pharmaceutical Alliance (pCPA). Provincial funding typically waits until these negotiations are finalized, a process that can add 18 to 24 months of waiting for patients in desperate need.

Ontario's FAST program fundamentally flips this script. For select high-priority cancer drugs, the province begins public funding before pCPA negotiations are complete, as soon as Canada's Drug Agency (CDA) issues a positive final recommendation. This move is projected to shorten the gap between federal approval and patient access by up to a full year.

To be eligible, drugs must be approved via Project Orbis, an international collaboration that expedites the review of promising cancer therapies. Itovebi joins a growing list of treatments accelerated through the program, including therapies for lung cancer, leukemia, and prostate cancer, signaling a broad commitment by the province to tackle access delays.

"For every Ontarian facing a cancer diagnosis, timely access to high-quality treatment can make all the difference," said Sylvia Jones, Deputy Premier and Minister of Health, in a statement. "Through the FAST program, our government is accelerating access to life-saving therapies, including Itovebi, bringing hope, peace of mind, and transformative care to those who need it most."

A Breakthrough for a Difficult-to-Treat Cancer

The clinical need for Itovebi is acute. It targets a specific subset of breast cancer—the most common type, HR-positive, which accounts for about 70% of all cases—that also carries a PIK3CA gene mutation. This mutation is found in approximately 40% of HR-positive breast cancers and is associated with a poorer prognosis and resistance to standard endocrine therapies.

For these patients, whose cancer has returned or spread after initial treatment, options have been limited. The clinical data for Itovebi, when used in combination with palbociclib and fulvestrant, is compelling. Study results showed the regimen more than doubled the median progression-free survival—the length of time a patient lives with the disease without it getting worse—from 7.3 months to 15 months compared to the combination of palbociclib and fulvestrant alone. This represents more than just a statistic; it is months of invaluable, higher-quality time for patients and their families.

"The approval of Itovebi through Ontario's FAST program represents a major milestone in timely access to breast cancer therapies," stated Cathy Ammendolea, Board Chair of the Canadian Breast Cancer Network. "This treatment provides people diagnosed with metastatic, HR+ PIK3CA mutated breast cancer with a targeted option for their disease."

A Chorus of Approval: Government and Advocates Applaud Progress

The announcement has been met with widespread praise from patient advocacy groups, who have long campaigned against the systemic delays in Canada's healthcare system. For years, they have shared stories of patients who felt abandoned while waiting for drugs that were already available in other countries.

"Timely access to effective therapies is critical," said Kimberly Carson, CEO of Breast Cancer Canada. "Ontario's FAST program decision to fund Itovebi represents real progress for people living with HR-positive breast cancer, helping ensure patients and their care teams can access new treatment options without unnecessary delay."

The collaborative spirit behind the program's success is being highlighted as a model for future progress. The alignment of government policy, industry readiness, and patient advocacy created the momentum needed for such a significant systemic change.

MJ DeCoteau, Founder and Executive Director of Rethink Breast Cancer, emphasized the urgency that the program addresses. "For patients and families facing cancer, time matters. We are encouraged to see Itovebi as one of the first breast cancer therapies to move through Ontario's FAST program, and we applaud the province's leadership in recognizing the urgent access needs that patients face every day."

Ontario's Bold Move and the National Ripple Effect

While Ontarians celebrate this victory, the question looms large: will the rest of Canada follow suit? The FAST program positions Ontario as a leader, but it also highlights the patchwork nature of drug access across the country. Patient advocates are now leveraging this success to pressure other provinces and territories to find ways to eliminate similar delays.

"We hope this patient-focused approach inspires other provinces to follow suit, so people across Canada can access promising cancer treatments sooner, no matter where they live," DeCoteau added.

In response to Ontario's initiative, the pCPA has announced its own Early Negotiation Process (ENP) to speed up national price negotiations for cancer drugs. However, the success of that initiative is yet to be seen, and it may not be as rapid as Ontario's direct-funding approach. There are concerns in the health policy community that if provinces act unilaterally, it could weaken the pCPA's collective bargaining power, potentially leading to higher drug prices in the long run.

For now, Roche Canada has confirmed it is committed to working with all jurisdictions and the pCPA to ensure patients outside of Ontario can access Itovebi as soon as possible. The path forward involves navigating these complex inter-provincial dynamics, but with Ontario's program as a working proof of concept, the argument for maintaining the status quo has grown significantly weaker.